Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significantly high » significantly higher (Expand Search), significantly change (Expand Search), significantly less (Expand Search)
high decrease » slight decrease (Expand Search), high degree (Expand Search), high disease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significantly high » significantly higher (Expand Search), significantly change (Expand Search), significantly less (Expand Search)
high decrease » slight decrease (Expand Search), high degree (Expand Search), high disease (Expand Search)
-
1261
-
1262
Baseline characteristics and potential independent risk factors for mortality of SFTS.
Published 2025Subjects: -
1263
Kinetics of coagulation parameters between the survivors and non-survivors during hospitalization.
Published 2025Subjects: -
1264
Restricted cubic spline models depicting the relationship between APTT and mortality risk in SFTS.
Published 2025Subjects: -
1265
-
1266
-
1267
Kaplan-Meier survival analysis curves according to the APTT levels between four groups.
Published 2025Subjects: -
1268
Dynamic profile of coagulation parameters between survivors and non-survivors in patients with SFTS.
Published 2025Subjects: -
1269
Multivariate logistic regression analysis on the risk factors associated with prolonged APTT.
Published 2025Subjects: -
1270
Characteristics and outcomes of participants categorized by serum APTT on admission.
Published 2025Subjects: -
1271
-
1272
-
1273
-
1274
-
1275
-
1276
-
1277
-
1278
Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>
Published 2025“…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P<sub>i</sub>‐induced VSMCs. …”
-
1279
-
1280